Salmonellosis ranks among the major diseases of commercial poultry, and its presence in poultry flocks is responsible for economic losses and risks related to public health. Vaccines are an important tool within integrated programmes to control salmonellosis. The purpose of this study was to assess cross-protection provided by the Poulvac® ST vaccine in the control of Salmonella Heidelberg in experimentally challenged 3-and 21-day-old birds. Eighty birds were identified and separated into four treatments (T1: vaccinated and challenged at 3 days of age, T2: unvaccinated and challenged at 3 days of age, T3: vaccinated and challenged at 21 days of age, and T4: unvaccinated and challenged at 21 days of age). The inoculum was produced from a Brazilian field strain of SH. At the end of the experiment, caecum and liver/ spleen samples were collected for quantitative and qualitative analysis of SH, respectively. Analysis of the liver/spleen showed that Poulvac® ST significantly (P ≤ 0.05) reduced the percentage of SH positivity in the group challenged at 3 days of age, while in the group challenged at 21 days this difference was almost considered significant (P = 0.1818). On the other hand, there was no statistically significant difference in SH count in the caecum (CFU/g) in the group challenged at 3 days, but for the group challenged at 21 days the SH counts were significantly (P ≤ 0.05) lower in the vaccinated group when compared to the positive control.ARTICLE HISTORY
Foodborne Salmonella infections in humans, which results from the consumption of contaminated poultry meat and eggs, are a major public health concern. Vaccination of animals against Salmonella is one strategy to prevent these infections and reduce the risks to public health. Live attenuated Salmonella enterica vaccines can confer protection against salmonellosis by inducing both cell-mediated and mucosal immune responses. This study assessed a live, attenuated Salmonella enterica Typhimurium (ST) vaccine in broiler chickens against a heterologous challenge with Salmonella Heidelberg (SH) by evaluating bacterial quantification, immune cells infiltration, and cytokine gene expression in the cecum. The treatments were: T1, non-vaccinated, non-challenged; T2, non-vaccinated, SH-challenged; T3, ST-vaccinated and SH-challenged. At 28 days of age, the ST-vaccinated group had significantly recovered reduction of SH in the crop (P<0,01) and cecum (P = 0,021) compared to the non-vaccinated SH-challenged group, with no significant changes (P˃0,05) in macrophages, T CD4+, or T CD8+ cells dynamics during the same period. Aerosol vaccination on the first day promoted greater interleukin-12 expression in the liver (P<0,05) and interleukin-10 expression and T CD8+ cells in the ileum 16 hours after housing. After prime-boosted oral immunization on the 13th day, the vaccinated group had greater expression of macrophages and T CD4+ cells in the liver (P<0,05) than the control group. Two doses of a live ST-attenuated vaccine promoted a partial cross-protective effect against SH strain UFPR1 challenge in broilers.
SUMMARYOver a span of nearly 4 yr, 246 bursal tissue samples were collected from Brazilian commercial broiler flocks (Gallus gallus) throughout the country and imprinted to sample collection cards (Flinders Technology Associates (FTA) cards). A total of 75 infectious bursal disease virus (IBDV) strains was successfully detected from the FTA card imprints and were submitted for further identification and molecular characterization. Nucleotide and predicted amino acid sequences of the IBDV surface protein VP2 were used to identify strains of the virus and place them into phylogenetic groups. The amino acids across the hypervariable region of VP2 in this study varied, but around half of all positive samples were classified as vaccine virus. The IBD viruses fell into 3 categories: variant IBDV, classic IBDV (vaccine), and very virulent (vv) IBDV. The samples were collected according to the 3 different vaccination strategies used in broilers: vectored vaccine, antigen-antibody complex vaccine, and conventional live vaccine. The genetic profile and frequency of the strains recovered from the flocks were highly dependent on the vaccination program. This information helps us gain a better understanding of the current landscape of IBD in Brazil and provides additional scientific data to support selection of the most effective vaccination strategies, products, and practices to prevent disease.
The purpose of this study was to investigate the effect of a new infectious bursal disease (IBD) immune complex vaccine on immune system response in both specific pathogen-free (SPF) and commercial birds. Evaluation of response to the vaccination in the two experiments was done by histopathological examination and serology. The results of this study have shown that immune complex vaccine with the V877 strain is quite safe in White Leghorn SPF birds in which there has been no participation of maternal antibodies. In commercial birds was also observed that the immune complex vaccine with the V877 strain acted synergistically with different levels of passive antibodies and the vaccine virus began to replicate as passive immunity decreased to provide the animal active immunological response. KEY-WORDS:Immune complex vaccine, Gumboro, serology, histopathology, poultry. RESUMOO objetivo desse estudo foi investigar o efeito de uma nova vacina de imunocomplexo contra a doença de Gumboro sobre o sistema imune de aves SPF e comerciais. A avaliação da resposta à vacinação foi realizada por meio de exame histopatológico e sorologia. Os resultados desse estudo demonstraram que a vacina de imunocomplexo com cepa V877 contra Gumboro é muito segura mesmo em aves SPF da linhagem White Leghorn nas quais não existia a participação de imunidade materna. Em aves comerciais também foi demonstrado que a vacina de imunocomplexo com a cepa V877 atuou sinergicamente com diferentes níveis de anticorpos passivos maternais, iniciando a replicação do vírus vacinal a partir do momento que a imunidade passiva diminui, para promover uma resposta imunológica ativa.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.